(ABSI) Absci - Overview
Stock: AI, Antibody, Discovery, Therapeutic, Platform
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 85.0% |
| Relative Tail Risk | -7.58% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.22 |
| Alpha | -68.26 |
| Character TTM | |
|---|---|
| Beta | 1.852 |
| Beta Downside | 1.377 |
| Drawdowns 3y | |
|---|---|
| Max DD | 66.06% |
| CAGR/Max DD | 0.02 |
Description: ABSI Absci December 29, 2025
Absci Corp (NASDAQ: ABSI) is a U.S.-based biotech that markets itself as a “data-first” generative-AI drug design platform, pairing large-language-model-style algorithms with high-throughput wet-lab automation to create novel antibody therapeutics. Its current pre-clinical pipeline includes ABS-101 (inflammatory bowel disease), ABS-201 (androgenic alopecia), ABS-301 (immuno-oncology), and ABS-501 (oncology). The firm leverages a network of R&D collaborations with entities such as PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle, and AMD.
Key quantitative touchpoints (as of the most recent filing) show a cash runway of roughly $45 million and a monthly burn rate near $3.5 million, implying ~12 months of liquidity absent additional financing. The AI-driven drug discovery sector is projected by McKinsey to grow at a CAGR of ≈ 40 % through 2030, driven by decreasing cost per candidate and faster lead identification-trends that directly benefit Absci’s value proposition. A material driver for ABSI’s valuation is the success of its AMD partnership, which provides access to high-performance GPU clusters that can cut model training time by up to 50 % versus standard cloud compute.
For a deeper quantitative view of ABSI’s risk-adjusted upside, you might explore the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -114.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.33 > 0.02 and ΔFCF/TA -3.37 > 1.0 |
| NWC/Revenue: 5161 % < 20% (prev 2935 %; Δ 2227 % < -1%) |
| CFO/TA -0.33 > 3% & CFO -80.7m > Net Income -114.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (143.8m) vs 12m ago 26.54% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.17% > 50% (prev 1.79%; Δ -0.62% > 0%) |
| Interest Coverage Ratio: -401.6 > 6 (EBITDA TTM -103.9m / Interest Expense TTM 289.0k) |
Altman Z'' -15.00
| A: 0.59 (Total Current Assets 175.0m - Total Current Liabilities 29.7m) / Total Assets 245.0m |
| B: -2.43 (Retained Earnings -595.2m / Total Assets 245.0m) |
| C: -0.48 (EBIT TTM -116.1m / Avg Total Assets 240.1m) |
| D: -17.16 (Book Value of Equity -594.7m / Total Liabilities 34.7m) |
| Altman-Z'' Score: -25.30 = D |
Beneish M -3.49
| DSRI: 1.00 (Receivables 1.00m/1.50m, Revenue 2.81m/4.21m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.87 (AQ_t 0.18 / AQ_t-1 0.21) |
| SGI: 0.67 (Revenue 2.81m / 4.21m) |
| TATA: -0.14 (NI -114.6m - CFO -80.7m) / TA 245.0m) |
| Beneish M-Score: -3.49 (Cap -4..+1) = AA |
What is the price of ABSI shares?
Over the past week, the price has changed by -10.76%, over one month by -21.66%, over three months by -18.83% and over the past year by -37.76%.
Is ABSI a buy, sell or hold?
- StrongBuy: 5
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ABSI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.1 | 198.1% |
| Analysts Target Price | 8.1 | 198.1% |
| ValueRay Target Price | 2.7 | -1.1% |
ABSI Fundamental Data Overview February 03, 2026
P/B = 2.1447
Revenue TTM = 2.81m USD
EBIT TTM = -116.1m USD
EBITDA TTM = -103.9m USD
Long Term Debt = 65.0k USD (from longTermDebt, last quarter)
Short Term Debt = 3.06m USD (from shortTermDebt, last quarter)
Debt = 6.22m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.26m USD (from netDebt column, last quarter)
Enterprise Value = 303.4m USD (449.6m + Debt 6.22m - CCE 152.5m)
Interest Coverage Ratio = -401.6 (Ebit TTM -116.1m / Interest Expense TTM 289.0k)
EV/FCF = -3.70x (Enterprise Value 303.4m / FCF TTM -81.9m)
FCF Yield = -27.01% (FCF TTM -81.9m / Enterprise Value 303.4m)
FCF Margin = -2911 % (FCF TTM -81.9m / Revenue TTM 2.81m)
Net Margin = -4071 % (Net Income TTM -114.6m / Revenue TTM 2.81m)
Gross Margin = unknown ((Revenue TTM 2.81m - Cost of Revenue TTM 53.8m) / Revenue TTM)
Tobins Q-Ratio = 1.24 (Enterprise Value 303.4m / Total Assets 245.0m)
Interest Expense / Debt = 0.72% (Interest Expense 45.0k / Debt 6.22m)
Taxrate = 21.0% (US default 21%)
NOPAT = -91.7m (EBIT -116.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.89 (Total Current Assets 175.0m / Total Current Liabilities 29.7m)
Debt / Equity = 0.03 (Debt 6.22m / totalStockholderEquity, last quarter 210.3m)
Debt / EBITDA = 0.03 (negative EBITDA) (Net Debt -3.26m / EBITDA -103.9m)
Debt / FCF = 0.04 (negative FCF - burning cash) (Net Debt -3.26m / FCF TTM -81.9m)
Total Stockholder Equity = 190.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -47.73% (Net Income -114.6m / Total Assets 245.0m)
RoE = -60.19% (Net Income TTM -114.6m / Total Stockholder Equity 190.4m)
RoCE = -60.93% (EBIT -116.1m / Capital Employed (Equity 190.4m + L.T.Debt 65.0k))
RoIC = -47.48% (negative operating profit) (NOPAT -91.7m / Invested Capital 193.1m)
WACC = 12.57% (E(449.6m)/V(455.8m) * Re(12.74%) + D(6.22m)/V(455.8m) * Rd(0.72%) * (1-Tc(0.21)))
Discount Rate = 12.74% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 24.62%
Fair Price DCF = unknown (Cash Flow -81.9m)
EPS Correlation: 64.70 | EPS CAGR: 37.39% | SUE: 4.0 | # QB: 1
Revenue Correlation: -43.48 | Revenue CAGR: -30.15% | SUE: -1.49 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.17 | Chg30d=-0.008 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=-0.70 | Chg30d=-0.032 | Revisions Net=-1 | Growth EPS=+11.7% | Growth Revenue=+414.8%